JP2020513016A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020513016A5 JP2020513016A5 JP2019554855A JP2019554855A JP2020513016A5 JP 2020513016 A5 JP2020513016 A5 JP 2020513016A5 JP 2019554855 A JP2019554855 A JP 2019554855A JP 2019554855 A JP2019554855 A JP 2019554855A JP 2020513016 A5 JP2020513016 A5 JP 2020513016A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- antibacterial
- composition according
- synthetic cationic
- antimicrobial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000844 anti-bacterial effect Effects 0.000 claims 59
- 239000008194 pharmaceutical composition Substances 0.000 claims 54
- 125000002091 cationic group Chemical group 0.000 claims 22
- 229920001184 polypeptide Polymers 0.000 claims 22
- 102000004196 processed proteins & peptides Human genes 0.000 claims 22
- 108090000765 processed proteins & peptides Proteins 0.000 claims 22
- 230000000845 anti-microbial effect Effects 0.000 claims 18
- 239000008365 aqueous carrier Substances 0.000 claims 16
- 150000001413 amino acids Chemical group 0.000 claims 14
- 230000002209 hydrophobic effect Effects 0.000 claims 10
- 239000000654 additive Substances 0.000 claims 6
- 230000000996 additive effect Effects 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 6
- 239000008367 deionised water Substances 0.000 claims 5
- 229910021641 deionized water Inorganic materials 0.000 claims 5
- 230000001954 sterilising effect Effects 0.000 claims 5
- 238000004659 sterilization and disinfection Methods 0.000 claims 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 3
- 235000004279 alanine Nutrition 0.000 claims 3
- 230000003110 anti-inflammatory effect Effects 0.000 claims 3
- 229960000310 isoleucine Drugs 0.000 claims 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 3
- 239000004474 valine Substances 0.000 claims 3
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 230000036074 healthy skin Effects 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 2
- 230000000813 microbial effect Effects 0.000 claims 2
- 230000007935 neutral effect Effects 0.000 claims 2
- 102000009027 Albumins Human genes 0.000 claims 1
- 108010088751 Albumins Proteins 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 241000699666 Mus <mouse, genus> Species 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 claims 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims 1
- 241000191967 Staphylococcus aureus Species 0.000 claims 1
- 241000191963 Staphylococcus epidermidis Species 0.000 claims 1
- 206010052428 Wound Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims 1
- 210000000683 abdominal cavity Anatomy 0.000 claims 1
- 206010000269 abscess Diseases 0.000 claims 1
- 230000002776 aggregation Effects 0.000 claims 1
- 238000004220 aggregation Methods 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- 238000011109 contamination Methods 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 238000002224 dissection Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 235000001727 glucose Nutrition 0.000 claims 1
- 235000011187 glycerol Nutrition 0.000 claims 1
- 229960001340 histamine Drugs 0.000 claims 1
- 239000000017 hydrogel Substances 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000008520 organization Effects 0.000 claims 1
- 230000003204 osmotic effect Effects 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 235000010356 sorbitol Nutrition 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 238000010610 time kill assay Methods 0.000 claims 1
- 230000001988 toxicity Effects 0.000 claims 1
- 231100000419 toxicity Toxicity 0.000 claims 1
- 230000000472 traumatic effect Effects 0.000 claims 1
- 210000001635 urinary tract Anatomy 0.000 claims 1
- 239000000811 xylitol Substances 0.000 claims 1
- 235000010447 xylitol Nutrition 0.000 claims 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims 1
- 229960002675 xylitol Drugs 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023028902A JP7656643B2 (ja) | 2017-04-06 | 2023-02-27 | 能力と安全性が増強された組成物および抗菌合成カチオン性ポリペプチド類を局所的に適用する使用 |
| JP2025049135A JP2025090864A (ja) | 2017-04-06 | 2025-03-24 | 能力と安全性が増強された組成物および抗菌合成カチオン性ポリペプチド類を局所的に適用する使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762482630P | 2017-04-06 | 2017-04-06 | |
| US62/482,630 | 2017-04-06 | ||
| PCT/US2018/026322 WO2018187617A1 (en) | 2017-04-06 | 2018-04-05 | Compositions and uses of locally applied antimicrobials with enhanced performance and safety |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023028902A Division JP7656643B2 (ja) | 2017-04-06 | 2023-02-27 | 能力と安全性が増強された組成物および抗菌合成カチオン性ポリペプチド類を局所的に適用する使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020513016A JP2020513016A (ja) | 2020-04-30 |
| JP2020513016A5 true JP2020513016A5 (https=) | 2021-05-06 |
Family
ID=63712780
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019554855A Pending JP2020513016A (ja) | 2017-04-06 | 2018-04-05 | 能力と安全性が増強された組成物および抗菌合成カチオン性ポリペプチド類を局所的に適用する使用 |
| JP2023028902A Active JP7656643B2 (ja) | 2017-04-06 | 2023-02-27 | 能力と安全性が増強された組成物および抗菌合成カチオン性ポリペプチド類を局所的に適用する使用 |
| JP2025049135A Pending JP2025090864A (ja) | 2017-04-06 | 2025-03-24 | 能力と安全性が増強された組成物および抗菌合成カチオン性ポリペプチド類を局所的に適用する使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023028902A Active JP7656643B2 (ja) | 2017-04-06 | 2023-02-27 | 能力と安全性が増強された組成物および抗菌合成カチオン性ポリペプチド類を局所的に適用する使用 |
| JP2025049135A Pending JP2025090864A (ja) | 2017-04-06 | 2025-03-24 | 能力と安全性が増強された組成物および抗菌合成カチオン性ポリペプチド類を局所的に適用する使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11285189B2 (https=) |
| EP (1) | EP3606543A4 (https=) |
| JP (3) | JP2020513016A (https=) |
| KR (2) | KR20240135875A (https=) |
| CN (1) | CN110740744A (https=) |
| AU (2) | AU2018249552A1 (https=) |
| BR (1) | BR112019020781A2 (https=) |
| CA (1) | CA3058901C (https=) |
| MX (2) | MX393548B (https=) |
| SG (1) | SG11201909016TA (https=) |
| WO (1) | WO2018187617A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102266659B1 (ko) | 2012-03-23 | 2021-06-17 | 아미크로베, 인코포레이티드. | 조직-적합성 특성을 갖는 항균물질의 조성물 및 용도 |
| CA3058901C (en) | 2017-04-06 | 2025-05-06 | Amicrobe, Inc. | Compositions and uses of topically applied antimicrobial agents offering improvements in performance and safety |
| JP2023501385A (ja) * | 2019-11-08 | 2023-01-18 | ユニバーシティ オブ ピッツバーグ － オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | 抗微生物ペプチドを含む組成物 |
| CN115397454A (zh) * | 2020-03-31 | 2022-11-25 | 立美基股份有限公司 | 通过辐照对自组装肽进行灭菌 |
| KR20220166832A (ko) * | 2020-04-08 | 2022-12-19 | 아미크로베, 인코포레이티드. | 바이러스 감염의 예방 및 치료를 위한 국소 적용 합성 아미노산 중합체의 조성물 및 용도 |
| US12371463B2 (en) | 2021-04-20 | 2025-07-29 | University of Pittsburgh—of the Commonwealth System of Higher Education | Methods and compositions for treatment of antibiotic-resistant bacterial infections |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5636643A (en) | 1991-11-14 | 1997-06-10 | Wake Forest University | Wound treatment employing reduced pressure |
| US6632922B1 (en) | 1998-03-19 | 2003-10-14 | The Regents Of The University Of California | Methods and compositions for controlled polypeptide synthesis |
| US6680365B1 (en) | 1998-03-19 | 2004-01-20 | The Regents Of The University Of California | Methods and compositions for controlled polypeptide synthesis |
| US6686446B2 (en) | 1998-03-19 | 2004-02-03 | The Regents Of The University Of California | Methods and compositions for controlled polypeptide synthesis |
| TW570805B (en) | 1998-09-01 | 2004-01-11 | Hoffmann La Roche | Water-soluble pharmaceutical composition in an ionic complex |
| EP1156781B1 (en) | 1999-02-26 | 2005-06-08 | Chiron Corporation | Microemulsions with adsorbed macromolecules and microparticles |
| ES2260291T3 (es) | 2000-09-28 | 2006-11-01 | Chiron Corporation | Microparticulas para la administracion de acidos nucleicos heterologos. |
| US6835536B2 (en) | 2001-08-21 | 2004-12-28 | Micrologix Biotech Inc. | Antimicrobial cationic peptides and formulations thereof |
| WO2003020797A1 (en) | 2001-08-30 | 2003-03-13 | The Regents Of The University Of California | Transition metal initiators for controlled poly (beta-peptide) synthesis from beta-lactam monomers |
| JP2003171463A (ja) | 2001-12-06 | 2003-06-20 | Chisso Corp | ポリリジン及びその製造法 |
| CA2443472A1 (en) | 2002-02-07 | 2003-08-14 | Ophtecs Corporation | Liquid formulation for contact lenses |
| CA2509365C (en) | 2002-12-09 | 2012-08-07 | American Bioscience, Inc. | Compositions and methods of delivery of pharmacological agents |
| DE602004012269T2 (de) | 2003-07-11 | 2009-04-30 | Theravance, Inc., South San Francisco | Quervernetzte glycopeptid-cephalosporin-antibiotika |
| WO2005018701A1 (en) | 2003-08-25 | 2005-03-03 | Kane Biotech Inc. | Synergistic antimicrobial compositions and methods of inhibiting biofilm formation |
| WO2005063278A1 (en) | 2003-12-30 | 2005-07-14 | Bioactive Polymers Ab | Surface protection of exposed biological tissues |
| US20080145383A1 (en) | 2004-03-12 | 2008-06-19 | Intercell Ag | Method for Solubilizing Peptide Mixtures |
| EP1927597B1 (en) | 2004-08-18 | 2016-11-02 | Novabiotics Limited | Antibacterial peptides |
| CA2607841C (en) | 2005-06-06 | 2015-11-24 | Novozymes A/S | Polypeptides having antimicrobial activity and polynucleotides encoding same |
| US20080139450A1 (en) | 2005-07-01 | 2008-06-12 | Srinivasa Madhyastha | Antimicrobial Compositions and Uses Thereof |
| US20070190110A1 (en) | 2006-02-10 | 2007-08-16 | Pameijer Cornelis H | Agents and devices for providing blood clotting functions to wounds |
| CA2671461C (en) | 2006-12-01 | 2014-01-28 | The Regents Of The University Of California | Vesicles of self-assembling block copolymers and methods for making and using the same |
| CA2691645A1 (en) | 2007-06-25 | 2008-12-31 | Lipopeptide Ab | New medical products |
| EP2192923A2 (en) | 2007-08-27 | 2010-06-09 | Massachusetts Institute of Technology | Bi-functional polymer-attached inhibitors of influenza virus |
| CA2727428A1 (en) | 2008-06-19 | 2009-12-23 | Nippon Shinyaku Co., Ltd. | Drug carrier |
| CN102256613B (zh) | 2008-10-20 | 2014-09-10 | 莫伊莱麦屈克斯公司 | 用于治疗或者预防粘连的多肽 |
| WO2010083589A1 (en) | 2009-01-23 | 2010-07-29 | Kane Biotech Inc. | Biofilm-removing antimicrobial compositions and uses thereof |
| GB0905451D0 (en) | 2009-03-31 | 2009-05-13 | Novabiotics Ltd | Biofilms |
| EA037276B1 (ru) | 2010-04-27 | 2021-03-03 | Лисандо Аг | Способы устранения или уменьшения бактериальной биопленки |
| JP5902171B2 (ja) | 2010-08-23 | 2016-04-13 | ザ・リージェンツ・オブ・ザ・ユニバーシティー・オブ・カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ | 高抗微生物活性および低毒性を有する材料の組成物および使用 |
| JP5613779B2 (ja) | 2011-01-19 | 2014-10-29 | 株式会社メニコン | コンタクトレンズ用液剤 |
| US9781949B2 (en) | 2011-03-31 | 2017-10-10 | The University Of Massachusetts | Antimicrobial delivery systems, methods of manufacture, and methods of use thereof |
| KR102266659B1 (ko) | 2012-03-23 | 2021-06-17 | 아미크로베, 인코포레이티드. | 조직-적합성 특성을 갖는 항균물질의 조성물 및 용도 |
| DE102014101663A1 (de) | 2014-02-11 | 2015-08-13 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Synthetische artifizielle Peptide mit antimikrobieller Wirkung |
| US10351599B2 (en) | 2014-09-19 | 2019-07-16 | Tensive Controls, Inc. | Anti-microbial peptides |
| AU2015338969B2 (en) * | 2014-10-30 | 2020-08-27 | Biomet Manufacturing, Llc | Methods of preventing surgical site infections |
| JP2016113373A (ja) * | 2014-12-11 | 2016-06-23 | エスポ化学株式会社 | 抗菌性、抗ウイルス性を有する水溶性組成物 |
| CA3058901C (en) | 2017-04-06 | 2025-05-06 | Amicrobe, Inc. | Compositions and uses of topically applied antimicrobial agents offering improvements in performance and safety |
| WO2019169324A1 (en) | 2018-03-02 | 2019-09-06 | January Therapeutics, Inc. | Nanoparticle compositions |
-
2018
- 2018-04-05 CA CA3058901A patent/CA3058901C/en active Active
- 2018-04-05 BR BR112019020781A patent/BR112019020781A2/pt unknown
- 2018-04-05 KR KR1020247029282A patent/KR20240135875A/ko not_active Ceased
- 2018-04-05 EP EP18780547.8A patent/EP3606543A4/en active Pending
- 2018-04-05 AU AU2018249552A patent/AU2018249552A1/en not_active Abandoned
- 2018-04-05 CN CN201880037998.9A patent/CN110740744A/zh active Pending
- 2018-04-05 WO PCT/US2018/026322 patent/WO2018187617A1/en not_active Ceased
- 2018-04-05 MX MX2019011912A patent/MX393548B/es unknown
- 2018-04-05 JP JP2019554855A patent/JP2020513016A/ja active Pending
- 2018-04-05 US US16/500,288 patent/US11285189B2/en active Active
- 2018-04-05 SG SG11201909016T patent/SG11201909016TA/en unknown
- 2018-04-05 KR KR1020197032623A patent/KR20200018400A/ko not_active Ceased
-
2019
- 2019-10-03 MX MX2022007904A patent/MX2022007904A/es unknown
-
2022
- 2022-03-08 US US17/654,021 patent/US12268722B2/en active Active
-
2023
- 2023-02-27 JP JP2023028902A patent/JP7656643B2/ja active Active
- 2023-04-13 AU AU2023202283A patent/AU2023202283A1/en active Pending
-
2025
- 2025-03-24 JP JP2025049135A patent/JP2025090864A/ja active Pending
- 2025-03-25 US US19/090,034 patent/US20260041728A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020513016A5 (https=) | ||
| JP2023054375A5 (https=) | ||
| ES2886460T3 (es) | Sales de amonio di-cuaternario hechas de organosilicona y agentes antibacterianos | |
| JP5693470B2 (ja) | 銀イオンおよびメントールを含む消毒剤組成物並びにその使用 | |
| JP2015512403A5 (https=) | ||
| ES2343208T3 (es) | Gel para el tratamiento de heridas. | |
| US20220370680A1 (en) | Chitosan-containing formulations and methods of making and using the same | |
| KR20070102479A (ko) | 양이온성 방부 조성물 및 이의 사용 방법 | |
| RU2014137827A (ru) | Композиции и применение противомикробных материалов со свойствами биологической совместимости | |
| KR20120022930A (ko) | 은 설파디아진 및 키토산을 사용하여 제조한 약용 크림 및 이의 제조 방법 | |
| WO2016067283A1 (en) | Virucidal compositions comprising tannins for nasal and pulmonary administration | |
| US20250134946A1 (en) | Self-assembling amphiphilic peptide hydrogels for treatment of nerve injury | |
| ES2860098T3 (es) | Composición para la aplicación nasal | |
| US20240366717A1 (en) | Antimicrobial matrix formed from peptide hydrogels | |
| JP5535209B2 (ja) | 抗菌組成物 | |
| US20250144133A1 (en) | Colestyramine for treating wounds, bacterial infections of the skin, and inflammatory skin lesions | |
| ES2692834B2 (es) | Microesferas para el tratamiento de enfermedades de la piel o dermatologicas, osteomusculares y vasculares | |
| CA3188232A1 (en) | Antifungal matrix formed from peptide hydrogels | |
| ES2784275B2 (es) | Antiséptico de acción prolongada para el lavado higiénico por fricción y lavado pre-quirúrgico de manos | |
| RU2019133628A (ru) | Композиции и применения антимикробных средств для местного применения с улучшенными характеристиками и безопасностью | |
| RU2456978C1 (ru) | Мазь с фурацилином, лидокаином и дибунолом для комплексного лечения абсцессов и флегмон челюстно-лицевой области | |
| US20230149333A1 (en) | Compositions and uses of locally applied synthetic amino acid polymers for prevention and treatment of viral infections | |
| RU2682711C1 (ru) | Антисептическое средство | |
| JP2002205941A (ja) | 創傷創部感染治療剤 | |
| JP2018058789A (ja) | 抗菌性及び創傷治癒促進性を有する創傷治癒剤 |